141 related articles for article (PubMed ID: 36322814)
21. Decompensating esophoria as the presenting feature of myasthenia gravis.
Arblaster GE; Shipman TL; Pepper IM
J AAPOS; 2009 Jun; 13(3):310-1. PubMed ID: 19395293
[TBL] [Abstract][Full Text] [Related]
22. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial.
Sieb JP; Köhler W
Clin Neurol Neurosurg; 2010 Nov; 112(9):781-4. PubMed ID: 20663605
[TBL] [Abstract][Full Text] [Related]
23. Comparative effects of plasma exchange and pyridostigmine on respiratory muscle strength and breathing pattern in patients with myasthenia gravis.
Goti P; Spinelli A; Marconi G; Duranti R; Gigliotti F; Pizzi A; Scano G
Thorax; 1995 Oct; 50(10):1080-6. PubMed ID: 7491557
[TBL] [Abstract][Full Text] [Related]
24. Coexistence of Parkinson's disease and myasthenia gravis: a case report.
Kao KP; Kwan SY; Lin KP; Chang YC
Clin Neurol Neurosurg; 1993 Jun; 95(2):137-9. PubMed ID: 8344012
[TBL] [Abstract][Full Text] [Related]
25. Treatment of myasthenia gravis: focus on pyridostigmine.
Maggi L; Mantegazza R
Clin Drug Investig; 2011 Oct; 31(10):691-701. PubMed ID: 21815707
[TBL] [Abstract][Full Text] [Related]
26. Very late onset of myasthenia gravis: case report and brief review of the literature.
Oliveira R; Landeiro L; Lauterbach M
Acta Neurol Belg; 2020 Aug; 120(4):981-982. PubMed ID: 32052362
[No Abstract] [Full Text] [Related]
27. Plasma pyridostigmine levels in patients with myasthenia gravis.
Calvey TN; Chan K
Clin Pharmacol Ther; 1977 Feb; 21(2):187-93. PubMed ID: 837637
[TBL] [Abstract][Full Text] [Related]
28. [Serum levels of pyridostigmine in myasthenia gravis: methods and clinical significance].
Schumm F; Gaertner HJ; Wiatr G; Dichgans J
Fortschr Neurol Psychiatr; 1985 Jun; 53(6):201-11. PubMed ID: 2991094
[TBL] [Abstract][Full Text] [Related]
29. Prescription profile of pyridostigmine use in a population of patients with myasthenia gravis.
Machado-Alba JE; Calvo-Torres LF; Gaviria-Mendoza A; Augusto MejíA-Vélez C
Muscle Nerve; 2017 Dec; 56(6):1041-1046. PubMed ID: 28214292
[TBL] [Abstract][Full Text] [Related]
30. Neuromuscular function and plasma drug levels in pyridostigmine treatment of myasthenia gravis.
Breyer-Pfaff U; Schmezer A; Maier U; Brinkmann A; Schumm F
J Neurol Neurosurg Psychiatry; 1990 Jun; 53(6):502-6. PubMed ID: 2166138
[TBL] [Abstract][Full Text] [Related]
31. An unusual presentation of myasthenia gravis.
Chijoke A; Ogunmodele JA
West Afr J Med; 2009; 28(6):391-3. PubMed ID: 20486100
[TBL] [Abstract][Full Text] [Related]
32. Unilateral-external Ophthalmoplegia: ARare Presentation of Myasthenia Gravis.
Khan MS; Habib A; Basit I
J Coll Physicians Surg Pak; 2016 Nov; 26(11):142-143. PubMed ID: 28666511
[TBL] [Abstract][Full Text] [Related]
33. Myasthenia gravis and specific immunotherapy: monoclonal antibodies.
Cai XJ; Li ZW; Xi JY; Song HZ; Liu J; Zhu WH; Guo Y; Jiao Z
Ann N Y Acad Sci; 2019 Sep; 1452(1):18-33. PubMed ID: 31393614
[TBL] [Abstract][Full Text] [Related]
34. Factors associated with insensitivity to pyridostigmine therapy in Thai patients with ocular myasthenia gravis.
Chirapapaisan N; Tanormrod S; Chuenkongkaew W
Asian Pac J Allergy Immunol; 2007 Mar; 25(1):13-6. PubMed ID: 17891917
[TBL] [Abstract][Full Text] [Related]
35. Application of smart chemometric models for spectra resolution and determination of challenging multi-action quaternary mixture: statistical comparison with greenness assessment.
Mouhamed AA; Nadim AH; Mostafa NM; Eltanany BM
BMC Chem; 2024 Mar; 18(1):44. PubMed ID: 38431694
[TBL] [Abstract][Full Text] [Related]
36. A cause of reversible dysphagia: an unusual presentation of myasthenia gravis.
Brostoff JM; Dahdaleh D; Birns J
Eur J Intern Med; 2008 Jan; 19(1):70. PubMed ID: 18206608
[No Abstract] [Full Text] [Related]
37. [Myasthenia gravis. Longitudinal course and therapeutic aspects].
Klingler D; Necek S; Brücke P
Wien Med Wochenschr; 1978 Jun; 128(12):348-52. PubMed ID: 664725
[No Abstract] [Full Text] [Related]
38. Renal clearance of pyridostigmine in patients with myasthenia gravis.
Chan K; Calvey TN
Eur Neurol; 1977; 16(1-6):69-72. PubMed ID: 615720
[TBL] [Abstract][Full Text] [Related]
39. Effect of treatment with Fufang Huangqi decoction on dose reductions and discontinuation of pyridostigmine bromide tablets, prednisone, and tacrolimus in patients with type I or II myasthenia gravis.
Caifeng S; Jingsheng Z; Yi L; Xueshi H; Zhanyou W; Haiou P; Wenjun Q
J Tradit Chin Med; 2022 Oct; 42(5):810-817. PubMed ID: 36083490
[TBL] [Abstract][Full Text] [Related]
40. "Mummy, my eyelids are heavy": A case series of juvenile myasthenia gravis.
Krishna L; Abdul Jalil NF; Lott PW; Singh S; Choo MM
Eur J Ophthalmol; 2021 Mar; 31(2):NP119-NP122. PubMed ID: 31390886
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
